3 days popular7 days popular1 month popular3 months popular

A New Treatment For Kidney Disease-Associated Heart Failure?

(CKD) patients frequently suffer from mineral bone disorder, which causes and, eventually, .

Similar to patients with CKD, with low levels of the protein klotho (klotho hypomorphic ) also develop vascular calcification and have shorter life spans compared to normal .

In this issue of the , and colleagues at the University of Tübingen in Germany, found that treatment with the mineralocorticoid receptor antagonist spironolactone reduced vascular calcification in klotho hypomorphic mice and increased their life span.

In a companion Attending Physician article, Darryl Quarles of the University of Tennessee discusses the implications of these findings for the treatment of CKD patients.

TITLE: Spironolactone-sensitive vascular calcification and Pit-1-dependent osteoblastic differentiation in klotho-hypomorphic mice


ACCOMPANYING THE ATTENDING PHYSICIAN TITLE: Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new



Journal of Clinical Investigation